5 Cheap Stocks To Invest In (February 2021)


Are you interested in the cheap stocks to invest in (February 2021)? If so, come with us and let’s take a look at Insider Monkey’s latest article. It’s always difficult to determine which are the cheap stocks in the bull market that represents real values and will gain a lot in the long-run. Last year Bank of America surveyed more than 200 mutual, hedge and pension funds, and found that 78% of investors agreed the market was fairly overpriced. Insider Monkey warns us to be careful when investing in a bull market, saying it’s difficult to track the fast changes of the market. You can read useful advice in the article.

And now without a further ado let’s see Insider Monkey’s compilation about the 5 cheap stocks to invest in (February 2021). Cardinal Health, Inc. stands on the fifth spot on the compilation with 49 hedge funds and P/E ratio if 11.30. Cardinal is headquartered in Ohio and is involved in generic pharmaceutical, specialty and OTC healthcare products, and offers pharmacy management services to hospitals, while its instruments division sells medical, surgical and laboratory products. In the past twelve months the stock has seen a 12% decline, and in the end of the third quarter 2020 the firm announced adjusted EPS of $1.74, beating the Street estimates by $0.29. Cardinal increased its 2021 outlook for adjusted EPS to $5.85-$6.10 versus prior range of $5.65-$5.95. Bunge Limited is on the fourth spot with 51 hedge funds and P/E ratio if 10.24. Bunge operates in food processing, fertilizers and grain trading. In the end of December 2020, Bunge reported non-GAAP EPS of $3.05, above the Street’s estimates by $1.23. As of 2021, the company is projected EPS of at least $6, above the Street’s estimate of $5.50. Over the last 12 months, Bunge shares are up by a whopping 45%. The largest stakeholder is Moore Global Investments in Bunge. Biogen Inc. is the second company on the list with 63 hedge funds and a P/E ratio if 11.37. Biogen is headquartered in Switzerland and is involved in treatment of neurological diseases. The company is said to make a “financial reset” in 2021. In the end of December 2020 the firm announced a non-GAAP EPS of $4.58, missing the consensus by $0.18.  As for the outlook for 2021 revenues are projected to be between $10.45 billion and $10.75 billion. For more information about the cheap stocks to invest in, please click and see the entire article.